2,084 results match your criteria International Journal of Chronic Obstructive Pulmonary Disease [Journal]


Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.

Int J Chron Obstruct Pulmon Dis 2019 25;14:321-330. Epub 2019 Jan 25.

Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey,

Background: Antimicrobial peptides are effectors of host defence against infection and inflammation and can encourage wound repair.

Objectives: The objectives of this study were to investigate the plasma antimicrobial peptide LL-37 and nuclear factor-kappaB (NF-κB) levels in patients with stable COPD compared with a control group and to highlight their importance in immune inflammation.

Methods: One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S185602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354692PMC
January 2019

Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples.

Int J Chron Obstruct Pulmon Dis 2019 23;14:311-319. Epub 2019 Jan 23.

Centre for Heart Lung Innovation, James Hogg Research Centre, St Paul's Hospital, Vancouver, BC, Canada,

Background: Etiologies of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are heterogeneous. We phenotyped severe AECOPD based on molecular pathogen detection of sputum samples collected at hospitalization of COPD patients and determined their outcomes.

Methods: We phenotyped 72 sputum samples of COPD patients who were hospitalized with a primary diagnosis of AECOPD using a molecular array that detected common bacterial and viral respiratory pathogens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350828PMC
January 2019

Short-term effects of ambient air pollution on chronic obstructive pulmonary disease admissions in Beijing, China (2013-2017).

Int J Chron Obstruct Pulmon Dis 2019 23;14:297-309. Epub 2019 Jan 23.

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China,

Purpose: Evidence between air pollution and COPD admissions is inconsistent and limited in China. In this study, we aimed to explore the effects of air pollutants on COPD admissions in Beijing, China.

Patients And Methods: Daily COPD hospital admission visits derived from tertiary and secondary hospitals in Beijing were retrieved from January 2013 to February 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350834PMC
January 2019

Efficacy of a home discharge care bundle after acute exacerbation of COPD.

Int J Chron Obstruct Pulmon Dis 2019 22;14:289-296. Epub 2019 Jan 22.

Pulmonary, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital, Rouen, France,

Purpose: Acute exacerbations of COPD (AECOPD) are frequent and associated with a poor prognosis. A home discharge care bundle, the PRADO-BPCO program, has been set up by the French National Health System in order to reduce readmission rate after hospitalization for AECOPD. This program includes early consultations by the general practitioner, a nurse, and a physiotherapist after discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S178147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349078PMC
January 2019

Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.

Int J Chron Obstruct Pulmon Dis 2019 22;14:279-287. Epub 2019 Jan 22.

National Heart and Lung Institute, Imperial College London, London SW3 6LR, UK,

Background: Over the past two decades, there have been significant changes in the pharmacological management of COPD, due to an explosion of inhaler trials, and timely updation of national and international guidelines. We sought to describe temporal changes in prescribing practices in the United Kingdom, and some of the factors that may have influenced them.

Patients And Methods: COPD patients were identified from UK primary care nationally representative electronic healthcare records (Clinical Practice Research Datalink), between 2000 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349076PMC
January 2019

Minimal clinically important difference of 3-minute chair rise test and the DIRECT questionnaire after pulmonary rehabilitation in COPD patients.

Int J Chron Obstruct Pulmon Dis 2019 22;14:261-269. Epub 2019 Jan 22.

Faculty of Medicine, Université Grenoble-Alpes, Grenoble, France,

Background: The 3-minute chair rise test (3-minute CRT) and the Disability Related to COPD Tool (DIRECT) are two reproducible and valid short tests that can assess the benefit of pulmonary rehabilitation (PR) in terms of functional capacity and dyspnea in everyday activities.

Methods: We determined the minimal clinically important difference (MCID) of the DIRECT questionnaire and 3-minute CRT using distribution methods and anchor encroaches with a panel of eight standard tests in a cohort of 116 COPD patients who completed a PR program in real-life settings.

Results: The estimated MCID for the 3-minute CRT and DIRECT scores was five repetitions and two units, respectively, using separate and combined independent anchors. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/minimal-clinically-important-diffe
Publisher Site
http://dx.doi.org/10.2147/COPD.S187567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349077PMC
January 2019
2 Reads

Male current smokers have low awareness and optimistic bias about COPD: field survey results about COPD in Korea.

Int J Chron Obstruct Pulmon Dis 2019 21;14:271-277. Epub 2019 Jan 21.

Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang-si, South Korea,

Background: Smoking is a major risk factor for COPD. However, there is low COPD awareness among smokers. We conducted a field survey to investigate COPD awareness, optimistic bias associated with COPD, and COPD prevalence (using handheld spirometry) among current male smokers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S189859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345187PMC
January 2019
2 Reads
2.732 Impact Factor

Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.

Int J Chron Obstruct Pulmon Dis 2019 18;14:249-260. Epub 2019 Jan 18.

Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, ON, Canada.

Purpose: In contrast to randomized controlled trials (RCTs), changes in maintenance pharmacotherapy in clinical practice occur without a washout period. The Prospective cohort study for the real-life effectiveness evaluation of glycOpyrronium With indacatERol combination in the management of COPD in Canada (POWER) study evaluated the real-life effectiveness of indacaterol/glycopyrronium (IND/GLY) following a direct switch from a long-acting muscarinic antagonist (LAMA, tiotropium) or long-acting β-agonist (LABA)/inhaled corticosteroid (ICS) maintenance treatment (salmeterol/fluticasone [SFC]).

Methods: POWER was a single-cohort, prospective, multicenter, interventional study in which patients with moderate-to-severe COPD, who remained symptomatic on their current treatment of once-daily (od) tiotropium 18 µg or twice-daily (bid) SFC (any dose), were switched to treatment with open-label IND/GLY 110/50 µg od for 16 weeks. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/real-life-effectiveness-of-indacat
Publisher Site
http://dx.doi.org/10.2147/COPD.S185485DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343749PMC
January 2019
3 Reads

Erratum: Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum].

Authors:

Int J Chron Obstruct Pulmon Dis 2019 18;14:245. Epub 2019 Jan 18.

[This corrects the article on p. 1401 in vol. 12, PMID: 28546748. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343744PMC
January 2019

Erratum: Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum].

Authors:

Int J Chron Obstruct Pulmon Dis 2019 18;14:243. Epub 2019 Jan 18.

[This corrects the article on p. 183 in vol. 13, PMID: 29386887. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343745PMC
January 2019

Erratum: Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study [Corrigendum].

Authors:

Int J Chron Obstruct Pulmon Dis 2019 18;14:241. Epub 2019 Jan 18.

[This corrects the article on p. 1545 in vol. 13, PMID: 29785104. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343748PMC
January 2019

Cost-effectiveness of physical activity in the management of COPD patients in the UK.

Int J Chron Obstruct Pulmon Dis 2019 15;14:227-239. Epub 2019 Jan 15.

Academic Primary Care Division of Applied Health Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK.

Background: While the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines advise exercise to reduce disease progression, little investment in promoting physical activity (PA) is made by health care authorities. The purpose of this study was to estimate the cost-effectiveness of regular PA vs sedentary lifestyle in people with COPD in the UK.

Methods: Efficacy, quality of life, and economic evidence on the PA effects in COPD patients were retrieved from literature to serve as input for a Markov microsimulation model comparing a COPD population performing PA vs a COPD population with sedentary lifestyle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S181194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339649PMC
January 2019
1 Read

Nutritional status, dietary intake, and health-related quality of life in outpatients with COPD.

Int J Chron Obstruct Pulmon Dis 2019 14;14:215-226. Epub 2019 Jan 14.

School of Exercise and Nutrition Sciences, Faculty of Health Queensland University of Technology, Kelvin Grove, QLD, Australia,

Background: Malnutrition is common in patients with COPD; however, little is known about its impacts on health-related quality of life (QoL) among patients with COPD. This study aimed to explore the nutritional status and dietary intake among outpatients with COPD in Vietnam and its possible associations with QoL.

Methods: A cross-sectional study was carried out in COPD outpatients visiting the COPD management unit at the National Lung Hospital, Hanoi, Vietnam between May 2017 and July 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S181322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336029PMC
January 2019
1 Read

Is iron deficiency modulating physical activity in COPD?

Int J Chron Obstruct Pulmon Dis 2019 11;14:211-214. Epub 2019 Jan 11.

Pulmonology Department, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra (UPF), CIBERES, (ISCiii), Barcelona, Spain,

There is evidence that iron plays a key role in the adequate functioning of skeletal muscle. While it has been demonstrated that nonanemic iron deficiency (NAID) affects exercise tolerance and response to exercise training in patients with COPD, the impact on daily physical activities (DPAs) remains unknown. Eighteen COPD patients with NAID (ferritin <100 ng/mL or ferritin 100-299 ng/mL with a transferrin saturation <20%) and 18 COPD patients without this abnormality, matched for age, gender, and the degree of airflow limitation (control group), were enrolled to the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S182700DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333152PMC
January 2019

A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.

Int J Chron Obstruct Pulmon Dis 2019 9;14:199-210. Epub 2019 Jan 9.

Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.

Purpose: This study investigated the effect of dual bronchodilation with the long-acting β-receptor agonist/long-acting muscarinic antagonist combination, indacaterol/glycopyrronium (IND/GLY), on nighttime oxygenation, lung function, sleep quality, and symptoms in patients with moderate-to-severe COPD.

Patients And Methods: This was a 4-week, double-blind, multicenter, placebo-controlled, two-period crossover study. Patients were randomized in a 1:1 ratio to receive IND/GLY 110/50 µg once daily or matching placebo. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/a-randomized-trial-to-determine-th
Publisher Site
http://dx.doi.org/10.2147/COPD.S184127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330967PMC
January 2019
4 Reads

Rating sputum cell quality in clinical trials for asthma and COPD treatment.

Int J Chron Obstruct Pulmon Dis 2019 8;14:195-198. Epub 2019 Jan 8.

Fraunhofer ITEM, Clinical Airway Research - Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329344PMC
January 2019
2 Reads
2.732 Impact Factor

Effects of baseline symptom burden on treatment response in COPD.

Int J Chron Obstruct Pulmon Dis 2019 4;14:181-194. Epub 2019 Jan 4.

Medicines Evaluation Unit, University of Manchester, Manchester, UK.

Rationale: In symptomatic patients with COPD, the decision whether to initiate maintenance treatment with a single agent or a combination of long-acting bronchodilators remains unclear.

Objective: To investigate whether baseline symptomatic status influences response to tiotropium/olodaterol treatment.

Materials And Methods: Post hoc analysis of the randomized OTEMTO studies (NCT01964352; NCT02006732), in which patients with moderate-to-severe COPD received placebo, tiotropium 5 µg, tiotropium/olodaterol 2. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/effects-of-baseline-symptom-burden
Publisher Site
http://dx.doi.org/10.2147/COPD.S179912DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324615PMC
January 2019
3 Reads

The association between recent hospitalized COPD exacerbations and adverse outcomes after percutaneous coronary intervention: a nationwide cohort study.

Int J Chron Obstruct Pulmon Dis 2019 3;14:169-179. Epub 2019 Jan 3.

Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan,

Purpose: COPD is associated with coronary artery disease, and exacerbations are major events in COPD. However, the impact of recent hospitalized exacerbations on outcomes of percutaneous coronary intervention (PCI) remains underdetermined.

Patients And Methods: Using the National Health Insurance Research Database of Taiwan, we identified 215,275 adult patients who underwent first-time PCI between 2000 and 2012. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-association-between-recent-hos
Publisher Site
http://dx.doi.org/10.2147/COPD.S187345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322514PMC
January 2019
9 Reads

Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD.

Int J Chron Obstruct Pulmon Dis 2019 3;14:163-168. Epub 2019 Jan 3.

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China,

Background: COPD, characterized by chronic inflammation and airway remodeling, has significant pathological alterations in composition and deposition of the extracellular matrix. The expression of procollagen 1 C-terminal peptide (PICP) and collagen type 1 C-terminal telopeptide (ICTP), two major by-products in the synthesis and degradation of collagen, was shown to be positively correlated with inflammatory mediator levels in previous studies.

Purpose: In this study, we investigated whether the serum concentrations of PICP and ICTP were associated with the inflammation level for patients with stable COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322508PMC
January 2019
1 Read

Is COPD associated with alterations in hearing? A systematic review and meta-analysis.

Int J Chron Obstruct Pulmon Dis 2019 28;14:149-162. Epub 2018 Dec 28.

Department of Molecular Medicine, Health Research Institute, Thalassemia and Hemoglobinopathies Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran,

Background And Aims: COPD is an irreversible or persistent airflow obstruction, which affects up to 600 million people globally. The primary purpose of this systematic review was to explore the COPD-based alteration in the auditory system function by conducting a quantitative analysis of presently published data.

Materials And Methods: We systematically searched seven diverse electronic databases and manual searching of references to identify relevant studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S182730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312399PMC
December 2018
1 Read
2.732 Impact Factor

The relationship between steps of 6MWT and COPD severity: a cross-sectional study.

Int J Chron Obstruct Pulmon Dis 2019 28;14:141-148. Epub 2018 Dec 28.

Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China,

Background And Objective: The distance of 6-minute walk test (D6MWT) has been widely used in the assessment of functional status in patients with COPD, while very little attention has been paid to the role of steps of 6-minute walk test (S6MWT). The purpose of this study was to investigate the relationship between S6MWT and other physiologic parameters of COPD.

Patients And Methods: Seventy patients with stable COPD were enrolled consecutively in this cross-sectional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312395PMC
December 2018
2 Reads

Reduction in exacerbation of COPD in patients of advanced age using the Japanese Kampo medicine Dai-kenchu-to: a retrospective cohort study.

Int J Chron Obstruct Pulmon Dis 2019 27;14:129-139. Epub 2018 Dec 27.

Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Purpose: Patients with symptomatic COPD are recommended to use inhaled bronchodilators containing long-acting muscarinic receptor antagonists (LAMAs). However, bronchodilators may cause gastrointestinal adverse effects due to anticholinergic reactions, especially in advanced-age patients with COPD. Dai-kenchu-to (TU-100, Da Jian Zhong Tang in Chinese) is the most frequently prescribed Japanese herbal Kampo medicine and is often prescribed to control abdominal bloating and constipation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S181916DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311323PMC
December 2018
1 Read

Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.

Int J Chron Obstruct Pulmon Dis 2019 27;14:117-127. Epub 2018 Dec 27.

Mylan Global Respiratory Group, Mylan Pharma UK Ltd., Sandwich, Kent, UK,

Background: Formoterol fumarate inhalation solution (FFIS; Perforomist) is a long-acting β-agonist (LABA) marketed in the US as a nebulized COPD maintenance treatment. Because long-term LABA use was associated with a potential increased risk of exacerbation or death in asthma patients, the US Food and Drug Administration (FDA) requested a postmarketing commitment study to evaluate long-term safety in COPD patients.

Methods: This was a multicenter, randomized, double-blind, placebo-controlled, noninferiority study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S173595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311322PMC
December 2018
4 Reads

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β-agonist via dry-powder inhalers and pressurized metered-dose inhalers.

Int J Chron Obstruct Pulmon Dis 2019 24;14:101-114. Epub 2018 Dec 24.

Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.

Purpose: The aim of this study was to examine real-world differences in health care resource use (HRU) and costs among COPD patients in the USA treated with a dry powder inhaler (DPI) or pressurized metered-dose inhaler (pMDI) following a COPD-related hospitalization.

Methods: This retrospective analysis used the Truven MarketScan databases. Eligibility criteria included 1) age ≥40 years, 2) COPD diagnosis, 3) inpatient admission with a diagnosis of COPD exacerbation, 4) inhaled corticosteroid (ICS)/long-acting β-agonist (LABA) prescription within 10 days of hospital discharge (index date), and 5) continuous enrollment for 12 months preindex and 90 days postindex. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/differences-in-health-care-outcome
Publisher Site
http://dx.doi.org/10.2147/COPD.S177213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307496PMC
December 2018
2 Reads

Effects of community-based pulmonary rehabilitation in 33 municipalities in Denmark - results from the KOALA project.

Int J Chron Obstruct Pulmon Dis 2019 21;14:93-100. Epub 2018 Dec 21.

Municipality of Aalborg, Aalborg, Denmark.

Background: The positive impact of pulmonary rehabilitation (PR) in patients with COPD is well documented. However, little is known regarding the effect of this treatment in community-based settings. Since 2007, all Danish municipalities have been offering PR to patients with moderate to severe COPD, whereas patients with very severe disease or those suffering from many comorbidities were referred to outpatient hospital-based PR. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/effects-of-community-based-pulmona
Publisher Site
http://dx.doi.org/10.2147/COPD.S190423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306068PMC
December 2018
6 Reads

Cigarette smoke-induced RANKL expression enhances MMP-9 production by alveolar macrophages.

Int J Chron Obstruct Pulmon Dis 2019 20;14:81-91. Epub 2018 Dec 20.

Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China,

Background And Purpose: Cigarette smoke (CS) induces alveolar destruction through overproduction of proteinases including matrix metalloproteinase (MMP)-9 by alveolar macrophages (AMs). Receptor activator of nuclear factor-κB ligand (RANKL) functions in immune regulation and cytokine secretion; whether it is involved in CS-induced MMP-9 expression is unknown. The purpose of our study was to investigate the expression and functional role of RANKL pathway in MMP-9 production pertaining to the pathogenesis of COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304243PMC
December 2018
1 Read

Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD.

Int J Chron Obstruct Pulmon Dis 2019 20;14:73-80. Epub 2018 Dec 20.

Department of Respiratory Medicine, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, People's Republic of China,

Background: Plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are elevated in subjects with COPD, and high plasma NT-proBNP levels are correlated with a poor prognosis. Thus, it is crucial to decrease the plasma NT-proBNP levels at the early stage of disease. We aimed to assess the effects of short-term treatment of irbesartan and hydrochlorothiazide on plasma NT-proBNP levels and health-related quality of life (HRQOL) in subjects with acute exacerbations of COPD (AECOPD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S186872DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304246PMC
December 2018

Strain measurement on four-dimensional dynamic-ventilation CT: quantitative analysis of abnormal respiratory deformation of the lung in COPD.

Int J Chron Obstruct Pulmon Dis 2019 18;14:65-72. Epub 2018 Dec 18.

Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Nishihara, Okinawa, Japan,

Purpose: Strain measurement is frequently used to assess myocardial motion in cardiac imaging. This study aimed to apply strain measurement to pulmonary motion observed by four-dimensional dynamic-ventilation computed tomography (CT) and to clarify motion abnormality in COPD.

Materials And Methods: Thirty-two smokers, including ten with COPD, underwent dynamic-ventilation CT during spontaneous breathing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S183740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305131PMC
December 2018
3 Reads

COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.

Int J Chron Obstruct Pulmon Dis 2019 18;14:51-63. Epub 2018 Dec 18.

GlaxoSmithKline, Collegeville, PA, USA,

Background: Increasing availability of therapeutic options for COPD may drive new treatment pathways. This study describes COPD treatment in France, focusing on identifying initial treatment modifications in patients with COPD who either initiated long-acting bronchodilator (LABD)-based therapy or escalated to triple therapy (long-acting muscarinic antagonist [LAMA] + long-acting β-agonist [LABA] + inhaled corticosteroid [ICS]).

Methods: This retrospective analysis of patients with COPD in a large general practitioner database (IQVIA Longitudinal Patient Database) in France included two cohorts: Cohort 1 - new initiators of LABD-based therapy (LAMA, LABA, LAMA + LABA, LAMA + ICS, LABA + ICS or LAMA + LABA + ICS); Cohort 2 - patients escalating to triple therapy from mono- or dual-bronchodilator-based maintenance treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S181224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305135PMC
December 2018

Upper-extremity function prospectively predicts adverse discharge and all-cause COPD readmissions: a pilot study.

Int J Chron Obstruct Pulmon Dis 2019 18;14:39-49. Epub 2018 Dec 18.

Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA,

Background: Frailty can inform management approaches for individuals with COPD. However, inpatient measures of frailty are seldom employed because they are time-consuming or inapplicable for bed-bound patients. We investigated the feasibility and potential of an innovative sensor-based upper-extremity function (UEF) test for frailty assessment in predicting adverse outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S182802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305140PMC
December 2018
1 Read

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.

Int J Chron Obstruct Pulmon Dis 2019 18;14:27-37. Epub 2018 Dec 18.

Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.

Background: The efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY), administered twice daily (BID) via the innovative eFlow Closed System nebulizer (PARI Pharma GmbH, Starnberg, Germany), were demonstrated in two replicate, placebo-controlled, 12-week Phase III studies (GOLDEN 3 and GOLDEN 4). This report evaluates the efficacy and safety of GLY by baseline disease severity and age in the pooled GOLDEN 3 and GOLDEN 4 patient population (N=1,294).

Methods: Patients were grouped by baseline predicted post-bronchodilator FEV (<50%, ≥50%) and age (<65, ≥65, ≥75 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S184808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305132PMC
December 2018

Emphysema extent on computed tomography is a highly specific index in diagnosing persistent airflow limitation: a real-world study in China.

Int J Chron Obstruct Pulmon Dis 2019 17;14:13-26. Epub 2018 Dec 17.

Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China,

Objective: The diagnostic value of emphysema extent in consistent air flow limitation remains controversial. Therefore, we aimed to assess the value of emphysema extent on computed tomography (CT) on the diagnosis of persistent airflow limitation. Furthermore, we developed a diagnostic criterion for further verification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S157141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301435PMC
December 2018
1 Read

Disease awareness in patients with COPD: measurement and extent.

Int J Chron Obstruct Pulmon Dis 2019 17;14:1-11. Epub 2018 Dec 17.

Department of Internal Medicine, Respiratory Diseases and Allergy Clinic, University of Genova, Azienda Policlinico IRCCS San Martino, Genoa, Italy.

Background: Patient awareness of COPD refers to knowledge and acceptance of the disease and its treatment. Although it is relevant to management and outcomes, the disease awareness of patients is poorly investigated, and no validated questionnaires are currently available. We aimed to develop the novel Disease Awareness in COPD Questionnaire (DACQ), which was validated in relation to demographic and clinical features, in patients participating in the SATisfaction and Adherence to COPD Treatment (SAT) study. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/disease-awareness-in-patients-with
Publisher Site
http://dx.doi.org/10.2147/COPD.S179784DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301728PMC
December 2018
7 Reads

Post-discharge extended care contributes to the disease control of patients with COPD: a Chinese study.

Int J Chron Obstruct Pulmon Dis 2018;13:4005-4013. Epub 2018 Dec 14.

Department of Respiratory Medicine, Shenmu Hospital, Shenmu, Shaanxi, China,

Background: The aim of this study was to evaluate the efficacy of extended care in patients with COPD.

Patients And Methods: A total of 140 patients with GOLD-2 to -4 of COPD were included in final analysis. The care efficacy was evaluated by the St George's Respiratory Questionnaire 12-item General Health Questionnaire (GHQ-12), pulmonary function test and blood gas analysis. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/post-discharge-extended-care-contr
Publisher Site
http://dx.doi.org/10.2147/COPD.S177038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300378PMC
December 2018
6 Reads

Automated oxygen control with O2matic during admission with exacerbation of COPD.

Int J Chron Obstruct Pulmon Dis 2018;13:3997-4003. Epub 2018 Dec 14.

School of Biological Sciences, University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

Purpose: It is a challenge to control oxygen saturation (SpO) in patients with exacerbations of COPD during admission. We tested a newly developed closed-loop system, O2matic, and its ability to keep SpO within a specified interval compared with manual control by nursing staff.

Patients And Methods: We conducted a crossover trial with patients admitted with an exacerbation of COPD and hypoxemia (SpO ≤88% on room air). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S183762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300382PMC
December 2018
1 Read

Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD.

Int J Chron Obstruct Pulmon Dis 2018;13:3983-3995. Epub 2018 Dec 13.

Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada,

Background: The burden of symptoms varies markedly between patients with COPD and is only weakly correlated with lung function impairment. While heterogeneity in lung function decline and exacerbations have been previously studied, the extent of heterogeneity in symptoms and the factors associated with this heterogeneity are not well understood.

Methods: A sample of the general Canadian population ≥40 years with persistent airflow limitation was followed for up to 3 years. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/heterogeneity-in-the-respiratory-s
Publisher Site
http://dx.doi.org/10.2147/COPD.S184424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296193PMC
December 2018
11 Reads

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.

Int J Chron Obstruct Pulmon Dis 2018 12;13:3971-3981. Epub 2018 Dec 12.

Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Recently, two "fixed triple" single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting β-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have become available for patients with COPD. This review presents the clinical evidence that led to the approval of these triple therapies, discusses the role of ICS in patients with COPD, and presents data on the relative efficacy of "fixed triple" (ICS/LAMA/LABA) therapy vs LAMA, ICS/LABA, and LAMA/LABA combinations, and summarizes studies in which ICS/LABAs were combined with LAMAs to form "open triple" combinations. Of the five main fixed triple studies completed so far, three evaluated the efficacy and safety of an extrafine formulation of beclometasone dipropionate, formoterol fumarate, and glycopyrronium; the other two studies evaluated fluticasone furoate, vilanterol, and umeclidinium. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/triple-therapy-icslabalama-in-copd
Publisher Site
http://dx.doi.org/10.2147/COPD.S185975DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296179PMC
December 2018
6 Reads

Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.

Int J Chron Obstruct Pulmon Dis 2018;13:3937-3946. Epub 2018 Dec 13.

Pearl - a member of the AstraZeneca Group, Durham, NC, USA.

Background: Peak inspiratory flow (PIF) as generated through the resistance of a dry powder inhaler (DPI) device is a critical patient-dependent maneuver impacting the success of DPI medication delivery. Despite its importance, it is not routinely measured in clinical practice. Little is currently known about the relationship, if any, between PIF through DPI devices, routine spirometry and disease outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S174371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296178PMC
December 2018
3 Reads

New evaluation of trunk movement and balance during walking in COPD patients by a triaxial accelerometer.

Int J Chron Obstruct Pulmon Dis 2018;13:3957-3962. Epub 2018 Dec 7.

Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan,

Background: Individuals with COPD may experience ambulatory difficulty due to both effort intolerance arising from respiratory dysfunction and impaired balance control during walking. However, the trunk movement during walking has not been evaluated or adjusted for patients with COPD. The Lissajous index (LI) visually and numerically evaluates the left-right symmetry of the trunk movement during walking and is useful in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S184212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290864PMC
December 2018
1 Read

Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry.

Int J Chron Obstruct Pulmon Dis 2018;13:3947-3955. Epub 2018 Dec 6.

Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan,

Purpose: The GOLD report provides a framework for classifying COPD in a way that reflects its clinical impact and allows treatment recommendations. The GOLD 2017 proposes a new classification whereby patients are grouped as A-D according to their symptoms and history of exacerbations. However, the clinical characteristics and outcomes in these patients are not well documented. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-characteristics-and-outco
Publisher Site
http://dx.doi.org/10.2147/COPD.S182905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287647PMC
December 2018
11 Reads

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Int J Chron Obstruct Pulmon Dis 2018;13:3923-3936. Epub 2018 Dec 6.

Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa.

Background And Purpose: Fixed-dose combinations of a long-acting beta agonist and an inhaled corticosteroid are more effective than the individual components in COPD. The primary study objective was to demonstrate that the combination indacaterol acetate/mometasone furoate (IND/MF [QMF149]) was non-inferior to the twice-daily combination salmeterol xinafoate/fluticasone propionate (Sal/Flu) in terms of trough FEV at week 12 (day 85). Secondary objectives were to compare the efficacy of IND/MF (QMF149) vs Sal/Flu with respect to other lung function parameters, COPD exacerbations, symptoms and dyspnea, health status/health-related quality of life, and rescue medication use. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/indacaterol-acetatemometasone-furo
Publisher Site
http://dx.doi.org/10.2147/COPD.S179293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287650PMC
December 2018
4 Reads

Preliminary study: comparative effects of lung volume therapy between slow and fast deep-breathing techniques on pulmonary function, respiratory muscle strength, oxidative stress, cytokines, 6-minute walking distance, and quality of life in persons with COPD.

Int J Chron Obstruct Pulmon Dis 2018;13:3909-3921. Epub 2018 Dec 5.

Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Background: Lung volume therapy with the Voldyne device can improve lung volume and has a nonsignificant benefit on respiratory muscle strength via the slow deep-breathing technique (SDBT); whereas respiratory muscle training with a respiratory muscle trainer via the fast deep-breathing technique (FDBT) has produced a significant improvement in people with COPD. Thus, the aim of this study was to compare the efficiency of lung volume therapy with the Voldyne device with the SDBT and FDBT on pulmonary function, respiratory muscle strength, oxidative stress, cytokines, walking capacity, and quality of life (QoL) in people with COPD.

Methods: A total of 30 COPD patient volunteers with mild (stage I) to moderate (stage II) severity were randomized into two groups: SDBT (n=15) and FDBT (n=15). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/preliminary-study-comparative-effe
Publisher Site
http://dx.doi.org/10.2147/COPD.S181428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287646PMC
December 2018
7 Reads

Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan.

Int J Chron Obstruct Pulmon Dis 2018;13:3901-3907. Epub 2018 Dec 5.

Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.

Purpose: The 2017 GOLD ABCD classification shifts patients from groups C-D to A-B. Group A was the most widely distributed group in several studies. It would be useful to understand the characteristics for group A patients, but little has been reported concerning these issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S181938DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287652PMC
December 2018

Erratum: What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs [Erratum].

Authors:

Int J Chron Obstruct Pulmon Dis 2018 5;13:3899. Epub 2018 Dec 5.

[This corrects the article on p. 3485 in vol. 13, PMID: 30498338. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287644PMC
December 2018

Reassessing the BODE score as a criterion for listing COPD patients for lung transplantation.

Int J Chron Obstruct Pulmon Dis 2018;13:3963-3970. Epub 2018 Dec 10.

Service de Pneumologie, Department of Pneumology, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, CHU-UCL-Namur, Site Godinne, Yvoir, Belgium,

Background: The BODE score (incorporating body mass index, airflow obstruction, dyspnea and exercise capacity) is used for the timing of listing for lung transplantation (LTx) in COPD, based on survival data from the original BODE cohort. This has limitations, because the original BODE cohort differs from COPD patients who are candidates for LTx and the BODE does not include parameters that may influence survival. Our goal was to assess whether parameters such as age, smoking status and diffusion indices significantly influence survival in the absence of LTx, independently of the BODE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S182483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292230PMC
December 2018

The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation.

Int J Chron Obstruct Pulmon Dis 2018;13:3885-3894. Epub 2018 Nov 29.

University of Manchester, School of Health Sciences, Manchester, UK,

Background: In COPD disturbed sleep is related to exacerbation frequency, poor quality of life, and early mortality. We developed the Manchester Respiratory-related Sleep Symptoms scale (MaRSS) to assess sleep-time symptoms in COPD.

Methods: Focus groups including COPD and age-matched controls were used to develop an item-list, which was then administered to COPD patients and age-matched controls in a cross-sectional study. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-manchester-respiratory-related
Publisher Site
http://dx.doi.org/10.2147/COPD.S171140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276610PMC
November 2018
8 Reads

The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype.

Int J Chron Obstruct Pulmon Dis 2018 29;13:3879-3884. Epub 2018 Nov 29.

Department of Pneumology and Allergy, Medical University of Łódź, Łódź, Poland,

Introduction: Exacerbations of COPD (ECOPDs) are important events in the course of COPD, accelerating the rate of decline in lung function and increasing the mortality risk. A growing body of evidence suggests the significance of the "frequent exacerbator" phenotype. This phenotype seems to be associated with a more severe airflow limitation, symptoms, health-related quality of life impairment, and higher mortality. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-usefulness-of-soluble-receptor
Publisher Site
http://dx.doi.org/10.2147/COPD.S186170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276626PMC
November 2018
5 Reads

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.

Int J Chron Obstruct Pulmon Dis 2018;13:3867-3877. Epub 2018 Nov 28.

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

Background: Indacaterol 27.5 µg/glycopyrrolate 15.6 µg (IND/GLY 27. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S177097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276826PMC
November 2018
1 Read